Schroder Investment Management Group acquired a new position in Neuronetics Inc (NASDAQ:STIM) in the second quarter, HoldingsChannel reports. The institutional investor acquired 164,369 shares of the company’s stock, valued at approximately $4,374,000.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Polaris Venture Management Co. V L.L.C. bought a new position in Neuronetics in the second quarter worth $21,947,000. FMR LLC bought a new position in Neuronetics in the second quarter worth $10,169,000. Jennison Associates LLC bought a new position in Neuronetics in the second quarter worth $8,642,000. Redmile Group LLC bought a new position in Neuronetics in the second quarter worth $7,983,000. Finally, Wells Fargo & Company MN bought a new position in Neuronetics in the second quarter worth $7,734,000. Institutional investors and hedge funds own 62.32% of the company’s stock.
Shares of NASDAQ:STIM opened at $24.86 on Friday. Neuronetics Inc has a 1-year low of $20.70 and a 1-year high of $39.39. The company has a debt-to-equity ratio of -0.13, a quick ratio of 1.59 and a current ratio of 1.75.
Neuronetics (NASDAQ:STIM) last issued its quarterly earnings results on Tuesday, August 14th. The company reported ($30.60) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($29.76). The firm had revenue of $13.25 million during the quarter, compared to analysts’ expectations of $12.20 million. As a group, analysts expect that Neuronetics Inc will post -2.05 EPS for the current year.
Several brokerages have recently weighed in on STIM. Canaccord Genuity raised their price target on Neuronetics from $33.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday, August 15th. BTIG Research restated a “buy” rating and set a $33.00 price target on shares of Neuronetics in a report on Thursday, August 16th. Piper Jaffray Companies began coverage on Neuronetics in a report on Monday, July 23rd. They set an “overweight” rating for the company. JMP Securities began coverage on Neuronetics in a report on Monday, July 23rd. They set a “$26.02” rating and a $36.00 price target for the company. Finally, William Blair began coverage on Neuronetics in a report on Monday, July 23rd. They set an “outperform” rating for the company. Five analysts have rated the stock with a buy rating, Neuronetics has a consensus rating of “Buy” and an average target price of $36.33.
Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders. It offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment for adult patients with major depressive disorder. The company's NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed MRI-strength magnetic field, which induces electrical currents designed to stimulate specific areas of the brain associated with mood.
Featured Story: What are the Benefits of Index Funds?
Want to see what other hedge funds are holding STIM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neuronetics Inc (NASDAQ:STIM).
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.